Impact of SARS-CoV-2 variants on antibody tests

Since end of 2020, different SARS-CoV-2 variants have appeared worldwide − alpha (B.1.1.7), beta (B.1.351), gamma (P.1/B.1.1.128) and delta (B1.617.2) − which are in part more contagious than the original virus type and are therefore spreading more quickly within populations. These variants reveal genetic changes (mutations) in the so-called receptor binding domain (RBD), which is


The immune response after COVID-19 vaccination

Six months after the start of the COVID-19 vaccination campaign in Germany, half of the population has received at least one vaccination dose. According to the Federal Ministry of Health, 37.9% of them have already been fully vaccinated (as of 02.07.2021). Currently there are four different COVID-19 vaccines available in Germany, which differ slightly in


EUROIMMUN Launches SARS-CoV-2 NeutraLISA Assay to Determine the Neutralizing Capacity of Anti-SARS-CoV-2 Antibodies

Press Release CE marked assay based on well-established ELISA technology expands EUROIMMUN’s offerings for labs that seek to understand immune response to COVID-19. EUROIMMUN today announced the launch of the SARS-CoV-2 NeutraLISA assay, a surrogate neutralization test intended for the detection of neutralizing antibodies against SARS-CoV-2, the pathogen causing COVID-19. The CE marked assay adds


Oncgnostics and EUROIMMUN Announce Collaboration to Distribute Cervical Cancer Test GynTect

Press Release Jena / Lübeck (GER) – Biotechnology company oncgnostics GmbH is announcing a collaboration with the international diagnostics group EUROIMMUN, a PerkinElmer company. As part of the cooperation, EUROIMMUN will sell the cervical cancer test from oncgnostics GmbH, Gyn-Tect, in the European countries of Portugal, Italy, Turkey and Poland. The test is also expected

Scroll to Top